HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $50 price target.

April 30, 2024 | 10:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Genmab with a $50 price target.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to an uptick in the stock's price in the short term, as it reaffirms the analyst's bullish outlook on the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100